Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/ijd.17054 | DOI Listing |
Dermatol Ther (Heidelb)
November 2024
Department of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, Messina, Italy.
Background: Tirbanibulin 1% ointment has been licensed to treat non-hyperkeratotic actinic keratosis (AK) on the face and scalp in adults. Recent evidence suggests that, besides the antineoplastic effect, tirbanibulin may also confer substantial cosmetic benefits to patients.
Methods: We report a single-center retrospective study of patients affected by solar lentigines (SLs) and AKs in the context of field cancerization treated with tirbanibulin 1% ointment.
Dermatol Ther (Heidelb)
June 2024
Department of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, Messina, Italy.
Introduction: Tirbanibulin 1% ointment has been licensed to treat non-hyperkeratotic actinic keratosis (AKs) on the face and scalp in adults to ensure excellent patient tolerability due to the mild side effects and the brief application time compared to other topical therapies on the market. A growing body of evidence suggests that, beyond their primary function, the treatments for AKs and the cancerization field may inadvertently confer substantial cosmetic benefits to patients.
Methods: We report a single-center retrospective case series of patients referred to the Dermatology Unit of the University Hospital of Messina, Italy, between February and December 2023 seeking treatment for AKs in the context of photodamaged areas in which the application of tirbanibulin 1% ointment induced, besides clearance of AKs, anti-aging effects on both skin texture and solar lentigos.
Int J Dermatol
April 2024
Unit of Dermatology, University of Pisa, Pisa, Italy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!